C. Hermans

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +13

New section of the HITRAN database: Collision-induced absorption (CIA)

C. Richard, Iouli E. Gordon, Laurence S. Rothman et al. · Journal of Quantitative Spectroscopy and Radiative Transfer · 2011 · 397 citations

Natural Sciences, Chemistry, Physics +5

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

Ian Judson, John Radford, Martin Harris et al. · European Journal of Cancer · 2001 · 391 citations

Medicine, Oncology, Pharmacology +12

Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

Axel Le Cesne, Ian Judson, D. Crowther et al. · Journal of Clinical Oncology · 2000 · 258 citations

Medicine, Oncology, Pharmacology +15

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

A.T. van Oosterom, H.T. Mouridsen, Ole S. Nielsen et al. · European Journal of Cancer · 2002 · 164 citations

Medicine, Oncology, Pharmacology +13